Abstract: Mindray is seeking to raise at least USD500m via a Hong Kong listing. Huatai and JPM are the deal sponsors. This note covers Mindray's in vitro diagnostics, patient monitoring and life support, medical imaging, and peer valuation. We also discuss our preliminary thoughts on valuation.
COFOE MEDICAL, HENGRUI PHARMA, CHUNLI MEDICAL, FOSUN PHARMA, WUXI APPTEC, SH PHARMA, Mindray, SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING, COFOE MEDICAL TECHNOLOGY, Fosun Pharma, JIANGSU HENGRUI MEDICINE, SHANGHAI PHARMACEUTICALS, WUXI APPTEC, AUTOBIO DIAGNOSTICS, HAOHAI BIOTEC, Nihon Kohden, Sysmex, BEIJING CHUNLIZHENGDA MEDICAL INSTRUMENTS, SHANGHAI UNITED IMAGING HEALTHCARE, SH Haohai Biological, GE HealthCare Technologies Inc. Common Stock
Interested in the full report? Get in touch with our team.